WO2000045803A3 - Use of 5-aminosalicylates as antimicrobial agents - Google Patents

Use of 5-aminosalicylates as antimicrobial agents Download PDF

Info

Publication number
WO2000045803A3
WO2000045803A3 PCT/US2000/002802 US0002802W WO0045803A3 WO 2000045803 A3 WO2000045803 A3 WO 2000045803A3 US 0002802 W US0002802 W US 0002802W WO 0045803 A3 WO0045803 A3 WO 0045803A3
Authority
WO
WIPO (PCT)
Prior art keywords
growth
antimicrobial
bacterial species
clostridium
human
Prior art date
Application number
PCT/US2000/002802
Other languages
French (fr)
Other versions
WO2000045803A2 (en
Inventor
Henry C Lin
Mark Pimentel
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Priority to AU35879/00A priority Critical patent/AU3587900A/en
Publication of WO2000045803A2 publication Critical patent/WO2000045803A2/en
Publication of WO2000045803A3 publication Critical patent/WO2000045803A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Abstract

A method of inhibiting the growth of a bacterial species in a human or non-human vertebrate employs the antimicrobial (i.e., antibiotic) properties of 5-aminosalicylates. These antimicrobial properties are also employed in an antimicrobial method of inhibiting the growth of a bacterial species in a foodstuff and in foodstuffs containing a 5-aminosalicylate compound. Pharmaceutical compositions, foodstuffs, food containers, food-handling implements, cleansers, polishes, paints, sprays, soaps, or detergents comprise 5-aminosalicylate compounds, such as mesalamine, sulphasalazine, olsalazine, ipsalazine, salicylazobenzoic acid, balsalazide, or conjugated bile acids, including ursodeoxycholic acid-5-aminosalicylic acid. The present pharmaceutical compositions can be formulated for ingestive, colonic, or topical non-systemic delivery systems or for any systemic delivery systems. Formulation can be for human or veterinary administration. Using the method and pharmaceutical preparations the growth of bacterial species, such as Clostridium perfringens, Clostridium difficile, Clostridium botulinum, and Clostridium tetani can be inhibited.
PCT/US2000/002802 1999-02-08 2000-02-04 Use of 5-aminosalicylates as antimicrobial agents WO2000045803A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU35879/00A AU3587900A (en) 1999-02-08 2000-02-04 Use of 5-aminosalicylates as antimicrobial agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/246,645 US6326364B1 (en) 1999-02-08 1999-02-08 Use of 5-aminosalicylates as antimicrobial agents
US09/246,645 1999-02-08

Publications (2)

Publication Number Publication Date
WO2000045803A2 WO2000045803A2 (en) 2000-08-10
WO2000045803A3 true WO2000045803A3 (en) 2001-04-05

Family

ID=22931573

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/002802 WO2000045803A2 (en) 1999-02-08 2000-02-04 Use of 5-aminosalicylates as antimicrobial agents

Country Status (3)

Country Link
US (1) US6326364B1 (en)
AU (1) AU3587900A (en)
WO (1) WO2000045803A2 (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6765000B2 (en) * 1999-03-17 2004-07-20 Bonner Jr Ernest L Treatment for reactive arthritis or bursitis
US7884090B2 (en) 1999-03-17 2011-02-08 Ernest L. Bonner, Jr. Compositions and methods for the treatment of arthritis
US7691831B2 (en) 1999-03-17 2010-04-06 Ernest L. Bonner, Jr. Pharmaceutical combination and method for treatment of reactive arthritis or bursitis
TWI249519B (en) 2000-08-29 2006-02-21 Nobex Corp Immunoregulatory compounds and derivatives and methods of treating diseases therewith
GB0025556D0 (en) * 2000-10-18 2000-12-06 Eco Animal Health Ltd Treatment and prophylaxis of disease and infections of pigs and poultry
CA2359812C (en) 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
WO2005074908A1 (en) 2004-02-06 2005-08-18 Borody, Thomas, Julius Use of aminosalicylates in diarrhoea-predominent irritable bowel syndrome
KR20130028807A (en) * 2004-05-28 2013-03-19 샐릭스 파마슈티컬스 인코포레이티드 Prevention, treatment, and amelioration of radiation induced enteritis
HUE028158T2 (en) 2004-07-07 2016-12-28 Biocon Ltd Synthesis of azo bonded immunoregulatory compounds
ITRM20050389A1 (en) 2005-07-22 2007-01-23 Giuliani Spa COMPOUNDS AND THEIR SPECIFIC SALTS FOR PPAR RECEPTORS AND RECEPTORS FOR EGF AND THEIR USE IN MEDICAL FIELDS.
ITRM20050390A1 (en) * 2005-07-22 2007-01-23 Giuliani Spa COMPOUNDS AND THEIR SPECIFIC SALTS FOR PPAR RECEPTORS AND RECEPTORS FOR EGF AND THEIR USE IN MEDICAL FIELDS.
US8921344B2 (en) * 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
CA2816276A1 (en) * 2005-08-24 2007-03-01 Salix Pharmaceuticals, Inc. Balsalazide formulations and manufacture and use thereof
US7452872B2 (en) * 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
US7178823B1 (en) * 2005-09-23 2007-02-20 Jen-Lung David Tai Portable trailer
BRPI0622008A2 (en) * 2006-09-13 2011-12-20 Procter & Gamble Treatment Methods for Ulcerative Colitis
MX2009002786A (en) * 2006-09-13 2009-03-30 Procter & Gamble Methods of treatment for ulcerative colitis using aminosalicylate.
AU2013228061B2 (en) * 2006-11-03 2015-11-26 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
US20080159987A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Restless Legs Syndrome
US20080161337A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Chronic Prostatitis
US7645801B2 (en) * 2007-01-29 2010-01-12 Alaven Pharmaceutical Llc Reduced irritant enema for treatment of inflammatory bowel disease (IBD)
IE20070129A1 (en) * 2007-02-28 2008-12-24 Giuliani Int Ltd Ppar-gamma agonists stimulate enteric defensin expression
US7541384B2 (en) 2007-06-08 2009-06-02 Axcan Pharma Inc. Mesalamine suppository
US8217083B2 (en) * 2007-06-08 2012-07-10 Aptalis Pharma Canada Inc. Mesalamine suppository
US8436051B2 (en) 2007-06-08 2013-05-07 Aptalis Pharma Canada Inc. Mesalamine suppository
WO2009008006A2 (en) * 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions for gastrointestinal drug delivery
WO2010062369A2 (en) * 2008-11-03 2010-06-03 Tufts University Methods and compositions for inhibiting clostridium difficile spore germination and outgrowth
UA107562C2 (en) 2008-12-05 2015-01-26 METHOD OF TREATMENT OF PSORIASIS
DK2805746T3 (en) 2009-02-16 2020-08-10 Nogra Pharma Ltd Alkylamido compounds and uses thereof
BR112012004174A2 (en) * 2009-08-26 2016-03-29 Basf Se method to achieve an antimicrobial, preservative and / or inhibitory effect of microorganism adhesion, and use of the compound
US20110155749A1 (en) * 2009-12-24 2011-06-30 Kathryn Jeanne Neiheiser Germ guard label and methods for using germ guard label
MX358142B (en) 2010-04-26 2018-08-06 Salix Pharmaceuticals Ltd Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives for the treatment of males.
ES2846675T3 (en) 2010-08-09 2021-07-28 Inst Tecnologico Estudios Superiores Monterrey Antimicrobial, antibacterial and spore-germination-inhibiting activity of compounds extracted from avocado
PE20140887A1 (en) * 2011-02-04 2014-08-14 Optimer Pharmaceuticals Inc TREATMENT OF BACTERIAL INFECTIONS
CN116602950A (en) 2012-02-09 2023-08-18 诺格拉制药有限公司 Methods of treating fibrosis
US9055889B2 (en) 2012-03-20 2015-06-16 Commonwealth Laboratories, Inc. Method and apparatus for breath testing
CA2870490A1 (en) 2012-04-18 2013-10-24 Nogra Pharma Limited Methods of treating lactose intolerance
US20140141075A1 (en) 2012-11-21 2014-05-22 Warner Chilcott Company, Llc 5-aminosalicylic acid capsule formulation
IN2014MU00097A (en) * 2014-01-10 2015-08-21 Cadila Healthcare Ltd
US20160045442A1 (en) * 2014-08-13 2016-02-18 Cadila Healthcare Limited Stable pharmaceutical compositions of mesalamine
US20180000793A1 (en) 2015-02-06 2018-01-04 Ernesto Abel-Santos Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis
WO2017051208A1 (en) 2015-09-23 2017-03-30 Instituto Tecnológico y de Estudios Superiores de Monterrey Acetogenin molecules having antiplatelet and/or antithrombic activities, and methods and compositions thereof
US10932484B2 (en) 2016-10-19 2021-03-02 Instituto Tecnologico Y De Estudios Superiores De Monterrey Inhibitory activity of acetogenins against Listeria monocytogenes
CN109414037A (en) 2016-12-15 2019-03-01 雀巢产品技术援助有限公司 Adjust the composition and method of the bacterium in companion animals
US11091597B2 (en) * 2017-05-23 2021-08-17 The Research Foundation For The State University Of New York Packaging material and methods of using the same
EA202192207A1 (en) 2019-02-08 2021-10-27 Ногра Фарма Лимитед METHOD FOR OBTAINING 3- (4'-AMINOPHENYL) -2-METHOXYPROPIONIC ACID AND ITS ANALOGUES AND INTERMEDIATE COMPOUNDS

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3412090A (en) * 1964-07-10 1968-11-19 Geigy Chem Corp Organotin-substituted s-triazines
FR1605124A (en) * 1967-01-27 1973-03-16 Benzamide fungicides - applied by vaporisation with a cyanamide
US4863744A (en) * 1984-09-17 1989-09-05 Alza Corporation Intestine drug delivery
EP0468555A1 (en) * 1990-07-27 1992-01-29 GIULIANI S.p.A. Pharmaceutical composition for rectal administration of active principles exhibiting a prevalently topical medication action at the colon level
WO1992006690A1 (en) * 1990-10-22 1992-04-30 Borody Thomas J Treatment of non-inflammatory and non-infectious bowel disorders
JPH04300801A (en) * 1991-03-29 1992-10-23 Nippon Paint Co Ltd Intercalate composition of antibacterial substance
JPH0638591A (en) * 1992-07-10 1994-02-10 Ricoh Co Ltd Drive control method for stepping motor
WO1994028911A1 (en) * 1993-06-08 1994-12-22 Farmaceutisk Laboratorium Ferring A/S COMPOSITIONS FOR USE IN THE REGULATION OF SUBNORMAL pH VALUES IN THE INTESTINAL TRACT AND FOR TREATMENT OF BOWEL DISEASES
WO1997028795A1 (en) * 1996-02-07 1997-08-14 Joseph Chege Use of 3-amino-4-hydroxybenzoic acid for the treatment of retroviral infections
WO1998007458A1 (en) * 1996-08-19 1998-02-26 Korea Institute Of Science And Technology Surface coating method for metal implants
EP0882461A2 (en) * 1997-06-04 1998-12-09 Unitika Ltd. Medical device and production method thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1981002671A1 (en) 1980-03-20 1981-10-01 Ferring Farma Lab Pharmaceutical composition and method for the treatment of colitis ulcerosa and crohn's disease by oral administration
US4960765A (en) 1980-03-20 1990-10-02 Farmaceutisk Laboratorium Ferring A/S Pharmaceutical composition and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration
USRE33239E (en) 1983-09-06 1990-06-26 Farmaceutisk Laboratorium Ferring A/S Packaged stable enema solution or suspension containing 5-aminosalicyclic acid
US4657900A (en) 1983-09-27 1987-04-14 Rowell Laboratories Pharmaceutical article of manufacture comprising a bisulfite stabilized aqueous solution of 5-aminosalicylic acid and method
GB8909559D0 (en) 1989-04-26 1989-06-14 Smith Kline French Lab Pharmaceutical compositions
US5010069A (en) 1989-05-15 1991-04-23 Marion Laboratories, Inc. Stable liquid form of 5-aminosalicylic acid
US5120306A (en) 1990-03-21 1992-06-09 Gosselin Leon F Direct delivery of anti-inflammatories to the proximal small bowel
US5519014A (en) 1990-10-22 1996-05-21 Borody; Thomas J. Treatment of non-inflammatory and non-infectious bowel disorders
AU1907992A (en) 1991-06-07 1993-01-08 Byk Nederland Bv Pharmaceutical enema preparation
IT1277663B1 (en) 1995-09-28 1997-11-11 Crinos Industria Farmaco STABLE AQUEOUS SUSPENSIONS OF MESALAZINE FOR TOPICAL USE

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3412090A (en) * 1964-07-10 1968-11-19 Geigy Chem Corp Organotin-substituted s-triazines
FR1605124A (en) * 1967-01-27 1973-03-16 Benzamide fungicides - applied by vaporisation with a cyanamide
US4863744A (en) * 1984-09-17 1989-09-05 Alza Corporation Intestine drug delivery
EP0468555A1 (en) * 1990-07-27 1992-01-29 GIULIANI S.p.A. Pharmaceutical composition for rectal administration of active principles exhibiting a prevalently topical medication action at the colon level
WO1992006690A1 (en) * 1990-10-22 1992-04-30 Borody Thomas J Treatment of non-inflammatory and non-infectious bowel disorders
JPH04300801A (en) * 1991-03-29 1992-10-23 Nippon Paint Co Ltd Intercalate composition of antibacterial substance
JPH0638591A (en) * 1992-07-10 1994-02-10 Ricoh Co Ltd Drive control method for stepping motor
WO1994028911A1 (en) * 1993-06-08 1994-12-22 Farmaceutisk Laboratorium Ferring A/S COMPOSITIONS FOR USE IN THE REGULATION OF SUBNORMAL pH VALUES IN THE INTESTINAL TRACT AND FOR TREATMENT OF BOWEL DISEASES
WO1997028795A1 (en) * 1996-02-07 1997-08-14 Joseph Chege Use of 3-amino-4-hydroxybenzoic acid for the treatment of retroviral infections
WO1998007458A1 (en) * 1996-08-19 1998-02-26 Korea Institute Of Science And Technology Surface coating method for metal implants
EP0882461A2 (en) * 1997-06-04 1998-12-09 Unitika Ltd. Medical device and production method thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 197145, Derwent World Patents Index; AN 1971-72342S, XP002154689 *
DATABASE WPI Week 199249, Derwent World Patents Index; AN 1992-403352, XP002154690 *
KANG, G. ET AL: "Salicylate inhibits fimbriae mediated HEp-2 cell adherence of and hemagglutination by enteroaggregative Escherichia coli", FEMS MICROBIOL. LETT. (1998), 166(2), 257-265, XP000972470 *
SANDBERG-GERTZEN, H. ET AL: "In vitro effects of sulphasalazine, azodisal sodium, and their metabolites on Clostridium difficile and some other fecal bacteria", SCAND. J. GASTROENTEROL. (1985), 20(5), 607-12, XP000972467 *
TRIADAFILOPOULOS, GEORGE ET AL: "Comparative study of Clostridium difficile toxin A and cholera toxin in rabbit ileum", GASTROENTEROLOGY (1989), 97(5), 1186-92, XP000972469 *

Also Published As

Publication number Publication date
AU3587900A (en) 2000-08-25
US6326364B1 (en) 2001-12-04
WO2000045803A2 (en) 2000-08-10

Similar Documents

Publication Publication Date Title
WO2000045803A3 (en) Use of 5-aminosalicylates as antimicrobial agents
US5403587A (en) Disinfectant and sanitizing compositions based on essential oils
CA2260126C (en) Triclosan skin wash with enhanced efficacy
US9044403B2 (en) Sporicidal hand sanitizing lotion
KR100740393B1 (en) Minoxidil-Containing Preparations
EP1184031A3 (en) Foaming cosmetic cream for the treatment of fatty skins
IL148288A0 (en) Indolealkanol ester and indolealkylamide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
MX9801402A (en) Colourant composition for paint products.
DK0841899T3 (en) Preparations for topical administration of active ingredients
WO2006050298A3 (en) Benefit agent delivery system comprising ionic liquid
HUP9802725A3 (en) Phthalic acid diamide derivatives, agricultural and horticultural insecticide compositions containing these compounds as active ingredients and use thereof
WO2001032596A8 (en) Phenoxy carboxylic acid compounds and compositions for delivering active agents
CN102470077A (en) Natural preservative blend
CA2369444A1 (en) Pharmaceutical compositions of erythropoietin
WO2001017548A3 (en) Use of natriuretic peptides as antibiotically effective substances for treating bacterial infections
JPH05271073A (en) Anti (pseudomonas aeruginosa) agent
PL2048949T3 (en) Preservatives based on carboxylic anhydrides
WO2001005355A3 (en) Formulations for il-11
MY127749A (en) Liquid formulation
MX2010004763A (en) High concentration single phase glycol aerosol air sanitizer with dimethyl ether propellant.
CZ170495A3 (en) Vanillin composition in liquid form, process of its preparation and use
WO2013076061A2 (en) Method for straightening hair
US5565208A (en) Insect repellent aerosol
BR9608655A (en) Cleaning / sanitizing processes, compositions and / or articles for non-food inanimate surfaces
WO2001005254A3 (en) An antibacterial composition for control of gram positive bacteria in food

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase